Allarity Therapeutics Q3 2025 Results: Cash Decline, Negative Earnings, & Oncology Pipeline Updates
Allarity Therapeutics reports Q3 2025 results: modest cash decline, negative GAAP EPS of –$0.19, ongoing oncology pipeline, and a focus on securing new funding to advance its cancer therapeutics.
2 minutes to read